We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Rosetta Genomics Announces New York State Approval for miRview mets²

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Rosetta Genomics, Ltd announced that the New York State Department of Health has approved miRview® mets² for testing on patient samples from the state. New York is the only U.S. state that requires an independent regulatory review process for laboratory developed tests. With this approval, Rosetta Genomics can offer miRview® mets² in all 50 U.S. states. miRview® mets² is the Company's proprietary microRNA-based test that identifies the primary origin of many types of tumors of uncertain or unknown origin.

Approximately one third of all cancer patients are diagnosed with metastases, and a large proportion of those cases may have metastases whose primary origin is uncertain or unknown. Furthermore, in 3% to 5% of all cancer cases the primary origin is not found even after extensive clinical and pathological work up. In both scenarios, the use of miRview® mets² may assist physicians by confirming suspected origins, or providing possible new origins to explore which can affect treatment options.

"With approximately 200,000 cases of cancer of unknown primary (CUP) and difficult to diagnose metastatic cancer per year in the U.S., there is a pressing clinical need for more accurate identification of the tumor of origin," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "We are very pleased to have approval to market this important cancer diagnostic to the benefit of physicians and patients in New York."